medigraphic.com

2021, Number 3

<< Back Next >>

Rev Educ Bioquimica 2021; 40 (3)

El papel del ácido sialico en el desarrollo del cáncer de mama

Santiago OBL, Fernández RB, Hernández JJ, Gallego Velasco IB, García-Cruz LM, Hernández–Cruz PA

Language: Spanish
References: 36
Page: 89-99
PDF size: 432.64 Kb.


ABSTRACT

Sialic acids are typically found as terminal branches of N-glycans, O-glycans and glucosfingolipid gangliosides and occasionally covering the side chains of glycosylphosphaidilinositol (GPI) anchors. Sialic acid has a potential for biodiversity so for example in cancer increase the activity of the enzyme sialil transferase 6 (ST6Gal1) favors the formation of glycosydic binding in position α-2,6 in carbohydrates present in glycoconjugated cell membrane as part of the malignant phenotype. In this review we will address the role of sialic acid in breast cancer.


REFERENCES

  1. Varki A y Kornfeld S (2017). Essentials of Glycobiology, 3rd edition (Tercera ed.). Cold Spring Harbor (NY), E.U.: Cold Spring Harbor Laboratory Press.

  2. Taniuchi K, Cerny RL, Tanouchi A, Kohno K, Kotani N, Honke K, Saibara T, Hollingsworth MA. (2011). Overexpression of GalNActransferase GalNAc-T3 promotes pancreatic cancer cell growth. Oncogene, 30(49), 4843– 4854. https://doi.org/10.1038/onc.2011.194.

  3. Gallegos Velasco I B, Coutiño R, Martínez G y Hernández P (2008). Marcadores glicosilados en cáncer de mama. Revista de Educación Bioquímica 27:52-59

  4. Christiansen MN, Chik J, Lee L, Anugraham M, Abrahams JL, Packer NH. Cell surface protein glycosylation in cancer. (2014). Proteomics. 14:525-546.

  5. Zejian Zhang, Wuhrer, M. Holst, S. (2018). Serum sialylation changes in cancer. Glycoconjugate Journal, 35:139–160.

  6. Hakomori S. (2002) Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A. 99:10231-10233

  7. Suzuki T, Kitajima K, Inoue S, Inoue Y. (1995) N-glycosylation/deglycosylation as a mechanism for the post-translational modification/remodification of proteins. Glycoconj J. 12:183-193.

  8. B S GK, Surolia A. (2017) Comprehensive analysis of α 2-3-linked sialic acid specific Maackia amurensis leukagglutinin reveals differentially occupied N-glycans and C-terminal processing. Int J Biol Macromol. 94:114-121.

  9. Burchell JM, Beatson R, Graham R, Taylor- Papadimitriou J, Tajadura-Ortega V. (2018). O-linked mucin-type glycosylation in breast cancer. Biochem Soc Trans. 46:779-788.

  10. Bennett E, Mandel U, Clausen H, Gerken T, Fritz T y Tabak, L. (2012). Control of mucintype O-glycosylation: A classification of the polypeptide GalNAc-transferase gene family. Glycobiology. 22:736–756.

  11. Nissi M. Varki, Elizabeth Strobert, Edward J. Dick Jr., Kurt Benirschke, Ajit Varki (2011). Biomedical differences between human and nonhuman hominids: potential roles for uniquely human aspects of sialic acid biology. Annu Rev Pathol. 6:365-393.

  12. López Morales D, Vallejo V. (2007). Expresión de ácido sialico y de la β-galactósido α-2,6- sialiltransferasa en cáncer. Revista de Educación Bioquímica 26(3):93-98.

  13. Dall’Olio F, Chiricolo M (2001) Sialyltransferases in cancer. Glycoconj J 18:841-850.

  14. Dall’Olio F (2000) The sialyl-alpha2,6- lactosaminystructure: biosynthesis and functional role. Glycoconj J 17:669-676.

  15. Zhuang D, Yousefi S, Dennis JW (1991) Tn antigen and UDP-Gal:GalNAc alpha-R beta1- 3Galactosyltransferase expression in human breast carcinoma. Cancer Biochem Biophys. 12:185-98.

  16. Dhawan, P, and Richmond A. (2002) Role of CXCL1 in tumorigenesis of melanoma. J. Leukoc. Biol. 72, 9−18.

  17. Heo SH, Lee JY, Yang K.M, and Park KS. (2015) ELK3 Expression Correlates With Cell Migration, Invasion, and Membrane Type 1-Matrix Metalloproteinase Expression in MDAMB- 231 Breast Cancer Cells. Gene Expression 16, 197−203.

  18. Julien S, Krzewinski-Recchi MA, Harduin- Lepers A, Gouyer V, Huet G, Le Bourhis X, Delannoy P (2001) Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA. Glycoconj J. 18:883-893.

  19. Sewell R, Backstrom M, Dalziel M, Gschmeissner S, Karlsson H, Noll T, Gatgens J, Clausen H, Hansson GC, Burchell J, Taylor- Papadimitriou J (2006). The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. J Biol Chem. 281: 3586-3594.

  20. Julien S, Delannoy P (2003) Sialyl-Tn antigen in cancer: from diagnosis to therapy. Recent Research Developments in Cancer. Edited by: Pandalai SG, Kerala: Transworld Research Network, 5:185-199

  21. Kinney AY, Sahin A, Vernon SW, Frankowski RF, Annegers JF, Hortobagyi GN, Buzdar AU, Frye DK, Dhingra K (1997). The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. Cancer. 80:2240- 2249.

  22. Leivonen M, Nordling S, Lundin J, von Boguslawski K, Haglund C (2001) STn and prognosis in breast cancer. Oncology. 61: 299-305.

  23. 23 Kitagawa H, Paulson JC (1993) Cloning and expression of human Gal beta 1,3(4) GlcNAc alpha 2,3-sialyltransferase. Biochem Biophys Res Commun. 194:375-382. 10.1006/ bbrc.1993.1830.

  24. Cazet A, Julien S, Bobowski M, Bourchel l J, Delannoy P. (2010). Tumour-associated carbohydrate antigens in breast cancer. Breast Cancer Res 12, 204

  25. Matsuura N, Narita T, Mitsuoka C, Kimura N, Kannagi R, Imai T, Funahashi H, Takagi H (1997). Increased level of circulating adhesion molecules in the sera of breast cancer patients with distant metastases. Jpn J Clin Oncol. 27: 135-139.

  26. Kelly MP, Lee FT, Smyth FE, Brechbiel MW, Scott AM (2006) Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model. J Nucl Med. 47:716-725.

  27. Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O, Perez R, Ando S: (1996). Gangliosides expressed in human breast cancer. Cancer Res. 56:5165-5171.

  28. Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grosch S, Geisslinger G, Holtrich U, Karn T, Kaufmann M (2008) Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat., 112:41-52.

  29. Ruckhaberle E, Karn T, Rody A, Hanker L, Gatje R, Metzler D, Holtrich U, Kaufmann M (2009). Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer. J Cancer Res Clin Oncol. 135: 1005-1013.

  30. Goss PE, Baker MA, Carver JP, Dennis JW(1995) Inhibitors of carbohydrate processing: a new class of anticancer agents. Clin Cancer Res. 1:935-944.

  31. Tanaka T, Decuzzi P, Cristofanilli M, Sakamoto JH, Tasciotti E, Robertson FM, Ferrari M (2009). Nanotechnology for breast cancer therapy. Biomed Microdevices. 11:49-63.

  32. Lo NW, Dennis JW, Lau JT (1999). Overexpression of the alpha2,6-sialyltransferase, ST6Gal I, in a low metastatic variant of a murine lymphoblastoid cell line is associated with appearance of a unique ST6Gal I mRNA. Biochem Biophys Res Commun. 264:619-621.

  33. Taniguchi A (2008). Promoter structure and transcriptional regulation of human betagalactoside alpha2, 3-sialyltransferase genes. Curr Drug Targets., 9:310-316.

  34. Fuentes D, Avellanet J, Garcia A, Iglesias N, Gabri MR, Alonso DF, Vazquez AM, Perez R, Montero E (2010) Combined therapeutic effect of a monoclonal antiidiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model. Breast Cancer Res Treat. 120:379-389.

  35. Miles D, Papazisis K (2003) Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer. Clin Breast Cancer. 3 (Suppl 4):S134-S138.

  36. Julien S, Picco G, Sewell R, Vercoutter-Edouart AS, Tarp M, Miles D, Clausen H, Taylor- Papadimitriou J, Burchell JM /2009) Sialyl-Tn vaccine induces antibodymediated tumour protection in a relevant murine model. Br J Cancer. 100:1746-1754.




2020     |     www.medigraphic.com